| Tumour length measured on PET-CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer. | |
| | |
MedLine Citation:
|
PMID: 18651155 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To compare the accuracy of determining the most appropriate treatment approach based on a visual analysis on combined PET-CT, based on a visual analysis on PET (reviewed side-by-side with CT) and based on tumour length measurements (on PET and PET-CT). Tumour length, SUV, and the length-SUV index (length x SUV) were assessed (on PET and PET-CT) in benign oesophageal lesions (reflux oesophagitis; n = 29), in potentially curable stages of oesophageal cancer (Tis; T1-T3NxM0; curable group; n = 52), and in stages of oesophageal cancer best treated with palliative therapy (T4NxMx; TxNxM1; palliative group; n = 30). All lesions were histopathologically proven. Based on a visual analysis, PET-CT (sensitivity: 77%;specificity: 96%) was more accurate than PET (sensitivity: 67%; specificity: 89%) in assessing the appropriate treatment (curative vs. palliative). The length-SUV index was the most accurate quantitative parameter to distinguish palliative from curable stages (sensitivity: 93%; specificity: 90%) and to predict survival. The highest overall accuracy was reached when combining the results of the quantitative (length-SUV index) analysis with those of the qualitative (visual) analysis (sensitivity: 93%; specificity: 96%). Moreover, neither tumour length nor SUV can be used to distinguish reflux oesophagitis from early malignant lesions (T1 stage). Tumour length measured with PET-CT or PET is associated with stage and overall survival of oesophageal cancer and helps to guide the appropriate treatment approach. |
| | |
Authors:
|
Johannes B Roedl; Dushyant V Sahani; Rivka R Colen; Alan J Fischman; Peter R Mueller; Michael A Blake |
Related Documents
:
|
18577865 - Pre-operative staging with positron emission tomography in patients with pelvic recurre... 12097455 - Dual time point 18f-fdg pet for the evaluation of pulmonary nodules. 8662095 - Value of radioimmunoscintigraphy with technetium-99m labelled anti-cea monoclonal antib... 16777405 - The role of anatomic and functional staging in myeloma: description of durie/salmon plu... 7155075 - Structured noise in computed tomography: effects of periodic error sources. 2119115 - Mr imaging of tumor and tumorlike lesions of bone and soft tissue. |
Publication Detail:
|
Type: Controlled Clinical Trial; Journal Article Date: 2008-07-24 |
Journal Detail:
|
Title: European radiology Volume: 18 ISSN: 1432-1084 ISO Abbreviation: Eur Radiol Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2008-11-12 Completed Date: 2009-04-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9114774 Medline TA: Eur Radiol Country: Germany |
Other Details:
|
Languages: eng Pagination: 2833-40 Citation Subset: IM |
Affiliation:
|
Division of Abdominal and Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA. johannes.roedl@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Esophageal Neoplasms
/
diagnosis*,
therapy* Female Fluorodeoxyglucose F18 / diagnostic use* Humans Male Middle Aged Neoplasm Staging Patient Selection Positron-Emission Tomography / methods* Radiopharmaceuticals / diagnostic use Reproducibility of Results Sensitivity and Specificity Subtraction Technique* Tomography, X-Ray Computed / methods* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Which Iodine concentration in chest CT?--a prospective study in 300 patients.
Next Document: Role of nitric oxide synthase gene intron 4 and exon 7 polymorphisms in obstructive sleep apnea synd...